Anthera Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANTH research report →
Price Chart
About the company
Anthera Pharmaceuticals, Inc. , a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency.
- CEO
- Paul F. Truex
- IPO
- 2010
- Employees
- 21
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on ANTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.62K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -485.59%
- ROIC
- 3509.83%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-281,000-384.6%
- Op Income
- $-36,432,000
- Net Income
- $-16,935,000+68.4%
- EPS
- $-1.65+84.1%
- OCF Growth
- +24.6%
- FCF Growth
- +25.7%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -123.12
- RSI (14)
- 40
- Avg Volume
- 755
No earnings-call transcripts are available for ANTH yet.
- Free Float
- 99.8%
- Shares Outstanding
- 26.18M
- Float Shares
- 26.13M
of shares held by institutions
4 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Virtu Kcg Holdings LLC | 18.30K | ▲ 18.30K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 11, 18 | McManigle Mark Drew | other | 0 |
| Jan 5, 18 | THOMPSON JOHN CRAIG | other | 1,847,074 |
| Jan 5, 18 | SHANAHAN WILLIAM R JR | other | 567,876 |
| Jan 5, 18 | LIU MAY | other | 427,066 |
| Jan 5, 18 | TRUEX PAUL F | other | 84,705 |
| Jan 5, 18 | Thompson David E. | other | 84,705 |
| Jan 5, 18 | Sager Philip | other | 84,705 |
| Jan 5, 18 | Mueller Brian | other | 84,705 |
| Jan 5, 18 | Furse Brent | other | 84,705 |
| Jan 5, 18 | HENNEY CHRISTOPHER S | other | 84,705 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANTH coverage
Recent articles, reports, and earnings notes.
No research on ANTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANTH report →AMD and Cerbras Create A New Blueprint For Hardware
marketbeat.com · Jul 24
SpaceX Lost $1 Trillion In A Week. So Why Did Bond Investors Rush To Lend It $20 Billion?
benzinga.com · Jun 23
Anthera Pharmaceuticals (OTCMKTS:ANTH) Shares Cross Above Two Hundred Day Moving Average – What’s Next?
defenseworld.net · Mar 31
Anthera Pharmaceuticals (OTCMKTS:ANTH) Stock Passes Above Two Hundred Day Moving Average – What’s Next?
defenseworld.net · Feb 21
Anthera Pharmaceuticals (OTCMKTS:ANTH) Shares Cross Above Two Hundred Day Moving Average – What’s Next?
defenseworld.net · Jan 8
AM Best Assigns Issue Credit Ratings to Anthem, Inc.'s New Senior Unsecured Notes
businesswire.com · Mar 10
AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Announcement
businesswire.com · Feb 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.